Irelandjazzpharmaceuticals.com
Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on neuroscience and oncology, headquartered in Dublin with operations in North America and Europe. The company researches, develops, and commercializes therapies for sleep disorders, epilepsy, and hematologic and solid tumor cancers.
Its portfolio includes oxybate therapies—Xywav (for narcolepsy and idiopathic hypersomnia) and Xyrem (for narcolepsy); Epidiolex (cannabidiol) for rare epilepsies; Rylaze (recombinant asparaginase) for acute lymphoblastic leukemia; Vyxeos (daunorubicin and cytarabine liposome) for certain high-risk acute myeloid leukemia; Zepzelca (lurbinectedin) for small cell lung cancer; and Defitelio (defibrotide) for hepatic veno-occlusive disease. Jazz advances small molecules, biologics, and cannabinoid-based medicines through internal R&D and partnerships, and expanded its neuroscience capabilities with the 2021 acquisition of GW Pharmaceuticals. The company is listed on Nasdaq under the ticker JAZZ.
chemXplore tracks 1 project involving Jazz Pharmaceuticals.
Jazz Pharmaceuticals's role on them: Owner.
Phase 1b study to test zongertinib and zanidatamab combo in HER2-positive breast cancer, aiming to improve outcomes with dual HER2-targeted therapy.
Erika Taurel becomes CFO, overseeing financial management. Her experience spans pharmaceuticals, energy, and consumer products, with prior roles at Javara, Pfizer, and Jazz Pharmaceuticals.
The acquisition will create a leader in neuroscience, expanding product diversification and combining expertise in sleep, oncology, and epilepsy, with a robust pipeline and strong financial growth potential.
The new facility, supported by IDA Ireland, represents a €50 million investment and will employ up to 50 people. It has received FDA and Irish regulatory approval.
The new facility in Roscommon will cost $60-$68M, create 160 construction jobs, and 50 permanent jobs. Supported by IDA Ireland, it marks Jazz's first manufacturing site. Completion expected in 2016.
